Kole Krieger

Stories

Lumen Bio reports positive Phase 2 results for oral C. diff drug LMN-201

Leading commercial strategy for LMN-201

C. difficile infection recurs in roughly a quarter of treated patients, sending many back to the hospital for repeat rounds of antibiotics. Lumen Bioscience's oral biologic LMN-201 cut that recurrence to 9.1% in a randomized Phase 2 trial, versus 55.6% for placebo.

Updated 2 hours ago

Notable Quotes

Every recurrence we prevent is an opportunity to spare a patient a second, third, or subsequent C. difficile episode.

from Lumen Bio reports positive Phase 2 results for oral C. diff drug LMN-201 · Updated 2 hours ago

LMN-201 could expand hospital and primary care access, potentially becoming a routine part of C. difficile care and improving outcomes for millions of patients.

from Lumen Bio reports positive Phase 2 results for oral C. diff drug LMN-201 · Updated 2 hours ago